ARCI Controlled Therapeutic Medication Schedule for Horses - Version 3.2 Revised December 9, 2016.

Similar documents
ARCI Controlled Therapeutic Medication Schedule for Horses - Version 4.1 Revised January, 2019

ARCI Controlled Therapeutic Medication Schedule for Horses - Version 2.2 Revised April 2015

New Maryland Racing Medication Guidelines

Maryland Racing Commission Medication Guidelines

WITHDRAWAL TIME RECOMMENDATIONS ARIZONA RACE TRACKS MEET

CHAPTER 45. PROHIBITED PRACTICES AND EQUINE TESTING

2016 Massachusetts Gaming Commission Manual For Practicing Veterinarians

edition of the Association of Racing Commissioners International (ARCI s) Uniform Classifi cation Guidelines for Foreign Substances.

2017 Massachusetts Gaming Commission

Equine Medication Monitoring Program. Drugs and Medication Guidelines

EQUESTRIAN CANADA GUIDELINES FOR USE OF DRUGS AND MEDICATIONS

EQUINE DRUGS AND MEDICATIONS RULES

Prohibited Substances The NCHA rules do not allow and medications that can

Beef Quality Assurance Program

ARCI Medications and Prohibited Substances

2012 guidelines for DRUGS AND MEDICATIONS

BIO4 Antibiotics Expert Committee

2011 guidelines for DRUGS AND MEDICATIONS

DRUG REGULATIONS & WITHDRAWAL TIMES

Fundamentals of Pharmacology for Veterinary Technicians Chapter 16

Review of a Consequence of Highly Sensitive Drug Testing: The Need for Data on Analytical Pharmacological Relationships for Therapeutic Medications

Equine Drugs and Medications Rules

Drugs in the show ring: What you don t know can hurt your horse

Welcome to. Who Wants to be a Millionaire 50:50

Mitigating Pain in Livestock: What Options are Available

2017 GUIDELINES FOR DRUGS AND MEDICATIONS

Frank Zanzuccki, Executive Director. Calendar Reference: See Summary below for explanation of exception to calendar requirement.

TREATMENT RECORD REGISTER

Proceedings of the 56th Annual Convention of the American Association of Equine Practitioners - AAEP -

ALPHABETICAL REFERENCE GUIDE

DRUGS AND MEDICATIONS

Commonly Used Analgesics

YOUR COMPLETE SOURCE FOR MEDICAL MISSIONS SUPPLIES.

YOUR COMPLETE SOURCE FOR MEDICAL MISSIONS SUPPLIES.

NSAIDs Are You Following the Rules?

Meloxicam withdrawal time veterinarian bovine

List over prohibited substances and withdrawal times in Scandinavia, valid from January 1 st, 2019.

EPAR type II variation for Metacam

IMPORTANT SAFETY INFORMATION

Index. Note: Page numbers of article titles are in boldface type.

Prescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):

Equine Pharmaceuticals: Manufacturing/ Compounding Issues. Legal and Ethical Veterinary Compounding. Horse Industry Integrity

Case-Control Study of Pasture- and Endocrinopathy- Associated Laminitis in Horses

The Institutional Animal Care and Use Committee (IACUC) Aquatic Animals: Analgesia and Anesthesia formulary

Metacam 1.5 mg/ml oral suspension for dogs

List over prohibited substances and withdrawal times in Scandinavia, valid from September 3 rd 2018.

Please direct all inquiries to: United States Equestrian Federation, Inc. Equine Drugs and Medications Program 3760 Ridge Mill Drive, Hilliard, Ohio

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

Summary of Product Characteristics

Clinical Guidelines for Veterinarians Treating the Non Racing Performance Horse

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/127

We would love to work with you so you can prescribe the best treatments for your patients.

J. vet. Pharmacol. Therap. doi: /jvp SHORT COMMUNICATION H. K. KNYCH*, S. D. STANLEY*, R. M. ARTHUR & D. S. MCKEMIE*

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

20mL, 50mL, 100mL. 20mL, 50mL, 100mL. 20mL, 50mL, 100mL. 20mL, 50mL, 100mL. 20mL, 50mL, 100mL. 50mL, 100mL. 50mL, 100mL.

Pain management in equine patients therapy options

These are some brief notes on equine therapeutics, to cover broad principles and contraindications, doses are not given in most cases and should

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

POST-OPERATIVE ANALGESIA AND FORMULARIES

2016 Minnesota Racing Commission Manual For Veterinarians

FREEDOM OF INFORMATION (FOI) SUMMARY

Compounded Ophthalmic Formulations

GOBIERNO DE PUERTO RICO Administración de Servicios Médicos de Puerto Rico

Scientific Discussion post-authorisation update for Rheumocam extension X/007

UNTHSC. Institutional Animal Care and Use Committee. Title: Analgesics and Anesthesia in Laboratory Animals at UNTHSC. Document #: 035 Version #: 02

Quantification of Several Acidic Drugs in Equine Serum Using LC MS-MS

CONCORD DRUGS LIMITED Hyderabad

Compounded Ophthalmic Formulations

Diclofenac in Europe an update

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

LARC FORMULARY ANESTHESIA AND ANALGESIA IN LABORATORY ANIMALS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Table 2 - Medications and their ideal route of administration

Summary of Product Characteristics

Summary of Product Characteristics

NIH Anesthesia/Analgesia Formulary

T u l a n e U n i v e r s i t y I A C U C Guidelines for Rodent & Rabbit Anesthesia, Analgesia and Tranquilization & Euthanasia Methods

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

QUALITY HEALTH CARE YOUR PREFERRED PARTNER IN. For better health

Bureau of Laboratory Quality Standards Page 1 of 10

SUMMARY OF PRODUCT CHARACTERISTICS

Cascade. Guide for veterinarians if NO authorised medicinal product is available. Federation of Veterinarians of Europe

[amended May 5, 2005]

Prescription Medications Alphabetical Listing

List over prohibited substances and withdrawal times in Scandinavia, valid from January 1 st 2018.

Don t let arthritis slow down your dog!

INTRODUCTION TO WILDLIFE PHARMACOLOGY. Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre

Only for Intravenous Use in Beef and Dairy Cattle. Not for Use in Dry Dairy Cows and Veal Calves. For Intravenous or Intramuscular Use in Horses.

PRACTICAL ADVICE REGARDING THE 2004 EQUINE DRUGS AND MEDICATIONS RULE

DOSE ROUTE FREQUENCYREFERENCENOTES

SUMMARY OF PRODUCT CHARACTERISTICS

CLINICAL MASTITIS PERCEPTIONS OF KANSAS DAIRY PRODUCERS. J.R. Roberson 1

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33

Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor

Mouse Formulary. The maximum recommended volume of a drug given depends on the route of administration (Formulary for Laboratory Animals, 3 rd ed.

Transcription:

ARCI Schedule for Horses - Version 3.2 Revised December 9, 2016. Acepromazine 10 nanograms per milliliter as 2-(1- hydroxyethyl) promazine sulfoxide (HEPS) in urine Single intravenous dose of acepromazine at 0.05 University of California at Davis project metabolite HEPS Albuterol 1 nanogram per milliliter of urine 72 hours 720 micrograms total dose intra-nasal only 1. Based upon dosing up to 4 times per day European Horseracing Scientific Liaison Committee Data See Endnote Betamethasone 10 picograms per 7 days Intra-articular administration of 9 milligrams of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP (American Regent product #0517-0720-01) 2 RMTC Intra-articular dosing only - applicable analyte is betamethasone in plasma or Butorphanol 300 nanograms per milliliter of total butorphanol in urine or 2 nanograms of free butorphanol per milliliter per milliliter of plasma or Single intravenous dose of butorphanol as Torbugesic (butorphanol tartrate) at 0.1 Journal of Veterinary Therapeutics doi: 10.1111/j.1365-2885.2012.01385.x Applicable analytes are total butorphanol (drug and conjugates) in urine and butorphanol in plasma (the drug itself, not any conjugate) 1 Administration of albuterol by any means other than intra-nasally has a high likelihood in resulting in a positive finding. This specifically includes oral administration. Trainers and veterinarians are cautioned against using oral albuterol 2 Intramuscular administration of betamethasone acetate will result in plasma or concentrations that will exceed the Regulatory for weeks or even months, making the horse ineligible to race for an extended period.

2 Cetirizine 6 nanograms per 0.4 twice daily for 5 doses Do not administer ivermectin within 48 hours of a race if the horse has been administered cetirizine. Cimetidine 400 nanograms per 24 hours 20 twice daily for 7 doses Clenbuterol 140 picograms per milliliter of urine or Level of Detection in plasma or 14 days Oral administration of clenbuterol as Ventipulmin syrup (Boehringer-Ingelheim Vetmedica Inc., NADA 140-973) at 0.8 mcg/kg twice a day University of California at Davis; Boehringer-Ingelheim Vetmedica, Inc. clenbuterol Dantrolene 100 picograms per milliliter of 5-hydroxydantrolene in plasma or Oral administration of 500 milligrams of dantrolene as paste (compounding pharmacy) or capsule formulation (Proctor and Gamble) Journal of Veterinary Therapeutics 34, 238 246 Detomidine 2 nanograms per milliliter of carboxydetomidine in urine or 1 nanogram per milliter of detomidine in blood. 5 mg IV (once) KY EDRC, UC Davis/UF Study. Dormosedan used in.

3 Dexamethasone 5 picograms per milliliter of plasma or 72 hours Intramuscular and intravenous administration of dexamethasone sodium phosphate or oral administration of dexamethasone at 0.05 regardless of route RMTC dexamethasone in plasma or Diclofenac 5 nanograms per Five inch ribbon topical application of 1% diclofenac liposomal cream formulation. (Surpass Topical Anti- Inflammatory Cream, IDEXX Pharmaceuticals) Veterinary Therapeutics 6: 57-66 (2005) diclofenac in plasma or Dimethyl sulfoxide (DMSO) 10 micrograms per Intravenous ARCI model rule DMSO in plasma or Firocoxib 20 nanograms per 14 days Oral administration of firocoxib as EQUIOXX oral paste at a daily dose of 0.1 milligram per kilogram for four days RMTC firocoxib in plasma or

4 Furosemide 100 nanogram per 4 hours Single Intravenous dose of furosemide up to 500 milligram 3 ARCI model rule Must also have urine specific gravity < 1.010 for a violation. Glycopyrrolate 3 picograms per milliliter plasma or Single intravenous dose of 1 milligram of glycopyrrolate as Glycopyrrolate Injection, USP (American Regent product # 0517-4601-25) RMTC ; Journal of Veterinary Therapeutics doi: 10.1111/j.1365-2885.2011.01272.x glycopyrrolate in plasma or Guaifenesin 12 nanograms per 2 grams twice daily for 5 doses Isoflupredone 100 picograms per 7 days 10 milligrams total dose subcutaneous or 20 milligrams total dose in one articular space RMTC Study Lidocaine 20 picograms per milliliter of total 30Hlidocaine in plasma or 72 hours 200 milligrams of lidocaine as its hydrochloride salt administered subcutaneously European Horseracing Scientific Liaison Committee data; Iowa State University. Applies to total major hydroxylated metabolite (i.e., includes conjugates) 3 ARCI-011-020(F)(2)(d) and ARCI-025-020(F)(2)(d) state that the dose of Furosemide shall not exceed 500 milligrams nor be less than 150 milligrams.

5 Mepivacaine 10 nanograms total hydroxymepivacaine per milliliter of urine or above Level of Detection of mepivacaine in plasma or 72 hours Single 0.07 milligrams per kilogram subcutaneous dose of mepivacaine European Horseracing Scientific Liaison Committee data Methocarbamol 1 nanogram per milliliter of plasma or Single intravenous dose of 15 methocarbamol as Robaxin or 5 grams orally Journal of Veterinary Therapeutics doi: 10.1111/jvp.12068 methocarbamol in plasma or Methylprednisolone 100 picograms per See Dosing Specifications Total dose of methylprednisolone acetate suspension in one articular space. 4 The recommended withdrawal for methylprednisolone acetate is a minimum of 21 days at a 100 milligram dose Journal of Veterinary Therapeutics volume 37, Issue 2, pages 125 132, April 2014 methylprednisolone Omeprazole omeprazole sulfide - 10 nanograms per 24 hours Orally (2.2 grams) once daily for 4 doses GastroGuard used in the 4 Intramuscular administration of methylprednisolone acetate will result in plasma or concentrations that will exceed the Regulatory for weeks or even months, making the horse ineligible to race for an extended period. Please see Dosing Specifications for recommended withdrawal time.

6 Prednisolone 1 nanogram per milliliter of plasma or 1 milligram per kilogram orally prednisolone in plasma or Procaine penicillin (administration must be reported to Commission) 25 nanograms per Following entry to race Intramuscular RMTC reference notes online Mandatory surveillance of horse at owner s expense 6 hours before racing Ranitidine 40 nanograms per 24 hours 8 twice daily for 7 doses Triamcinolone acetonide 100 picograms per 7 days Total dose of 9 milligram in one articular space 5 Equine Veterinary Journal, 10.1111/evj.12059 (2013) triamcinolone acetonide in plasma or Xylazine 200 picograms per 200 milligrams intravenously University of California at Davis xylazine. 5 Intramuscular administration of triamcinolone acetonide will result in plasma or concentrations that will exceed the Regulatory for weeks or even months, making the horse ineligible to race for an extended period.

7 Non-Steroidal Anti-Inflammatory Drug (NSAID) Rules for Horses (Primary) Dosing Specifications Reference Notes (Secondary) Flunixin 20 nanogram per 32 hours Single intravenous dose of flunixin as Banamine (flunixin meglumine) at 1.1 milligram per kilogram University of California at Davis/RMTC Secondary antistacking threshold: 3.0 nanograms per (Administration prior) Ketoprofen 2 nanograms per 24 hours Single intravenous dose of ketoprofen as Ketofen at 2.2 HFL Sport Sciences/ and Council/RMTC Secondary antistacking threshold: 1 nanogram per milliliter of plasma or (Administration 48 hours prior) Phenylbutazone 2 micrograms per 24 hours Single intravenous dose of phenylbutazone at 4.0 ARCI model rule Secondary antistacking threshold: 0.3 micrograms per (Administration 48-hours prior) Samples collected may contain one of the NSAIDs in this chart at a concentration up to the Primary. Samples may also contain another of the NSAIDs in this chart up at a concentration up to the Secondary. No more than 2 of the NSAIDs in this chart may be present in any sample.

8 Recent Document Revisions Date Version Revision Revision Description Dec-16 3.2 Omeprazole Clarified threshold for omeprazole sulfide. Sep-16 3.1 Detomidine Amended threshold and dosing specifications. Mar-16 3 Omeprazole Amended threshold and dosing specifications Mar-16 3 Xylazine Amended threshold and dosing specifications Mar-16 3 Guaifenesin Added as New Substance to Schedule Mar-16 3 Cetirizine Added as New Substance to Schedule Mar-16 3 Ranitidine Added as New Substance to Schedule Mar-16 3 Cimetidine Added as New Substance to Schedule Apr-15 2.02 Methylprednisolone Directed readers to use Dosing Specification column for recommended withdrawal guideline. Apr-15 2.02 Furosemide Added clarifying language to Furosemide reflecting ARCI-011-020(F)(2)(d) and ARCI-025-020(F)(2)(d) minimum and maximum thresholds Apr-15 2.02 Added For Horses to Title Added the words for Horses to document title Apr-14 2.01 Methocarbamol Corrected dosage from 0.15 to 15 Apr-14 2 Dimethyl sulfoxide (DMSO) Removed oral from dosing specifications Apr-14 2 Xylazine Changed Note section from Applies to xylazine and xylazine metabolite to Applies to analyte xylazine

9 Apr-14 2 Xylazine Corrected typographical error in from 0.01ng/mg of plasma or to 0.01 nanogram per Apr-14 2 Isoflupredone Added Isoflupredone as New Substance to Schedule Apr-14 2 Albuterol Added Albuterol as New Substance to Schedule Apr-14 2 Flunixin, Ketoprofen, Phenylbutazone Apr-14 2 Flunixin, Ketoprofen, Phenylbutazone Added Secondary Anti-Stacking Created separate section for Non-Steroidal Anti-Inflammatory Drugs at end of Schedule, Relocated Flunixin, Ketoprofen, and Phenylbutazone to new section Apr-14 2 <All Substances> Changed Table Header from No Pre-Race Treatment Within to Apr-13 1 <All Substances> Original Schedule Adopted by ARCI Board of Directors